Lanreotide

Somatostatin Analog — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

Key facts

Lanreotide is an ofp drug in the Somatostatin Analog class catalogued in DrugCentral. It was first approved by the FDA in 2007. Its mechanism of action is classified as Somatostatin Receptor Agonists. DrugCentral lists 10 molecular targets, including SSTR2, SSTR5 and Sstr2. Recorded indications include Acromegaly, Hypersomatotropic gigantism and Thyroid-stimulating hormone secreting pituitary tumour.

• Approval status: ofp (first approved 2007 by the FDA).
• Drug class: Somatostatin Analog.
• Mechanism of action: Somatostatin Receptor Agonists.
• Molecular targets: SSTR2, SSTR5, Sstr2 and Sstr2 (10 listed in DrugCentral).
• Indications: Acromegaly, Hypersomatotropic gigantism and Thyroid-stimulating hormone secreting pituitary tumour.
• ATC code: H01CB03 (Somatostatin and analogues).
• Molecular formula: C54H69N11O10S2; molecular weight 1096.35 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Acromegaly
• Hypersomatotropic gigantism
• Thyroid-stimulating hormone secreting pituitary tumour

Contraindications (9)

• Bradycardia
• Calculus in biliary tract
• Disease of liver
• Disorder of gallbladder
• Hyperglycemia
• Hypertensive disorder
• Hypoglycemic disorder
• Hypothyroidism
• Impaired renal function disorder

Mechanism & targets

• Mechanism of action (MoA): Somatostatin Receptor Agonists
• Established pharmacologic class: Somatostatin Analog

Molecular targets (10)

Target	Gene	Action	Activity
Somatostatin receptor type 2	SSTR2	agonist	Ki 9.60
Somatostatin receptor type 5	SSTR5	agonist	Ki 9.30
Somatostatin receptor type 2	Sstr2	agonist	Ki 9.10
Somatostatin receptor type 2	Sstr2	agonist	Ki 8.80
Somatostatin receptor type 3	Sstr3	agonist	IC50 8.20
Somatostatin receptor type 3	SSTR3	agonist	Ki 8.00
Somatostatin receptor type 5	Sstr5	agonist	Ki 7.60
Somatostatin receptor type 4	SSTR4	unknown	Ki 7.18
Somatostatin receptor type 3	Sstr3	agonist	Ki 6.90
Somatostatin receptor type 1	SSTR1	unknown	Ki 6.30

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2020-12-12	PMDA	—	TEIJIN PHARMA LIMITED	Yes
2007-08-30	FDA	—	IPSEN PHARMA	Yes

ATC classification

ATC code	Therapeutic hierarchy
H01CB03	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS › PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES › HYPOTHALAMIC HORMONES › Somatostatin and analogues

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Diarrhoea	438.8
Inappropriate schedule of product administration	426.2
Injection site mass	424.3
Death	415.6
Insulin-like growth factor increased	358.9
Malignant neoplasm progression	325.2
Injection site pain	314.5
Abdominal pain	277.7
Off label use	266.3
Flatulence	215.9
Cholelithiasis	212.9
Neoplasm progression	211.6

Chemical structure

• Molecular formula: C₅₄H₆₉N₁₁O₁₀S₂
• Molecular weight: 1096.35 g/mol
• CAS number: —
• InChIKey: PUDHBTGHUJUUFI-PURAGXGVSA-N
• PubChem CID: 6918011

CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Lanreotide used for?

DrugCentral lists the following indications for Lanreotide: Acromegaly, Hypersomatotropic gigantism and Thyroid-stimulating hormone secreting pituitary tumour.

How does Lanreotide work?

Lanreotide is classified as Somatostatin Receptor Agonists; its molecular targets in DrugCentral include SSTR2 (agonist), SSTR5 (agonist), Sstr2 (agonist) and Sstr2 (agonist).

When was Lanreotide first approved?

Lanreotide was first approved by the FDA in 2007.

What drug class does Lanreotide belong to?

Lanreotide is in the Somatostatin Analog class.

What is the chemical formula of Lanreotide?

Lanreotide has the molecular formula C54H69N11O10S2 and a molecular weight of 1096.35 g/mol.

Sources

• DrugCentral drug card 1546 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201184 — compound record and bioactivity
• PubChem CID 6918011 — chemical identifiers
• DrugBank DB06791 — drug record
• FDA UNII 0G3DE8943Y — substance identity
• DailyMed: FDA labels for Lanreotide — current prescribing information (label search)
• UniProt P30874 (SSTR2) — target protein
• UniProt P35346 (SSTR5) — target protein
• UniProt P32745 (SSTR3) — target protein
• UniProt P31391 (SSTR4) — target protein
• UniProt P30872 (SSTR1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.